Victor Sam Wang, MD
Neurology · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 9
Offices
9 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Wang’s office to ask if they take your plan before you enroll.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$24,718
Medicare paid this office $24,718 for 46 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Botox | 11 | $10,045 | None |
| New patient visit (60+ min) | 29 | $5,613 | $194 |
| Long return visit (40+ min) | 15 | $3,760 | $171 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 11 | $1,538 | $140 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 24 | $1,381 | $29 |
See all 6 services
| Botox | 11 | $10,045 | None |
| New patient visit (60+ min) | 29 | $5,613 | $194 |
| Long return visit (40+ min) | 15 | $3,760 | $171 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 11 | $1,538 | $140 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 24 | $1,381 | $29 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 35 | $621 | $15 |
Who their Medicare patients are
46 Original Medicare patients in 2024. Average age 71 · Also on Medicaid 44% · Health risk score 0.91. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 59% · Depression 48% · Diabetes 24%.
The office billed $85,652, Medicare allowed $31,504 and paid $24,718; for 2,179 services of 15 kinds; $10,049 of it was for drugs given in the office and $14,669 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Drugs they prescribed that Part D paid
$77,657
Pharmacies billed $77,657 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 231) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
168 generic and 63 brand-name prescriptions · $77,657 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Aimovig | Migraine | 24 | $22,449 | $935 |
| Candesartan Cilexetil | None | 18 | $1,088 | $60 |
| Topiramate | None | 19 | $137 | $7 |
| Metoclopramide | None | 24 | $26 | $1 |
Year by year
| 2024 | 231 | 55 | 0% (0) | 27% | $77,657 |
| 2023 | 174 | 40 | None | None | $73,364 |
| 2022 | 230 | 43 | 0% (0) | None | $72,988 |
| 2021 | 139 | 32 | 0% (0) | None | $12,710 |
| 2020 | 86 | 28 | 0% (0) | 16% | $16,433 |
| 2019 | 27 | 13 | 0% (0) | None | $1,150 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Qulipta | 16 | $17,436 | $1,090 |
| Ubrelvy | 16 | $15,883 | $993 |
| Duloxetine | 14 | $640 | $46 |
2022: 8 drugs
| Ubrelvy | 18 | $25,880 | $1,438 |
| Ajovy | 12 | $8,845 | $737 |
| Duloxetine | 16 | $1,123 | $70 |
| Levetiracetam | 15 | $1,005 | $67 |
| Gabapentin | 15 | $847 | $56 |
| Topiramate | 11 | $175 | $16 |
| Divalproex | 11 | $111 | $10 |
| Metoclopramide | 12 | $19 | $2 |
2021: 3 drugs
| Levetiracetam | 12 | $482 | $40 |
| Memantine | 12 | $200 | $17 |
| Atorvastatin | 15 | $133 | $9 |
Money from drug and device companies
$15,119 in 2025
| 2025 | 8 | 27 | $13,731 | $15,119 |
| 2024 | 6 | 39 | None | $1,270 |
| 2023 | 8 | 42 | None | $1,334 |
| 2022 | 6 | 9 | $450 | $1,055 |
| 2021 | 5 | 7 | None | $447 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Qulipta | $9,782 | 14 payments
|
| Pfizer | Nurtec Odt | $5,013 | 6 payments
|
| Janssen Biotech | Tremfya | $144 | 1 payment
|
| Teva Pharmaceuticals USA | Ajovy | $67 | 2 payments
|
| Amneal Pharmaceuticals | Brekiya | $42 | 1 payment
|
| Axsome Therapeutics | Symbravo | $29 | 1 payment
|
See all 27 published payments
| Pfizer | Consulting · 2025-12-24 | Nurtec Odt | $1,525 |
| Abbvie | Meals · 2025-12-06 | Botox | $27 |
| Abbvie | Meals · 2025-12-05 | Ubrelvy | $100 |
| Abbvie | Meals · 2025-12-04 | Qulipta | $125 |
| Amneal Pharmaceuticals | Meals · 2025-12-04 | Brekiya | $42 |
| Pfizer | Paid to speak or teach · 2025-11-20 | Nurtec Odt | $3,150 |
| Pfizer | Meals · 2025-11-18 | Nurtec Odt | $102 |
| Abbvie | Meals · 2025-10-15 | Botox | $62 |
| Abbvie | Paid to speak or teach · 2025-10-02 | Qulipta | $1,181 |
| Abbvie | Paid to speak or teach · 2025-09-25 | Qulipta | $2,625 |
| Pfizer | Meals · 2025-09-25 | Nurtec Odt | $103 |
| Abbvie | Meals · 2025-09-12 | Qulipta | $19 |
| Abbvie | Travel · 2025-09-12 | Qulipta | $38 |
| Abbvie | Paid to speak or teach · 2025-08-04 | Qulipta | $2,625 |
| Teva Pharmaceuticals USA | Meals · 2025-07-29 | Ajovy | $21 |
| Abbvie | Meals · 2025-07-23 | Qulipta | $125 |
| Pfizer | Meals · 2025-07-22 | None | $106 |
| Abbvie | Paid to speak or teach · 2025-07-17 | Ubrelvy | $2,625 |
| Abbvie | Meals · 2025-07-10 | Ubrelvy | $125 |
| Abbvie | Travel · 2025-07-10 | Ubrelvy | $35 |
| Teva Pharmaceuticals USA | Meals · 2025-06-20 | Ajovy | $46 |
| Abbvie | Meals · 2025-06-19 | Qulipta | $70 |
| Axsome Therapeutics | Meals · 2025-06-19 | Symbravo | $29 |
| Janssen Biotech | Meals · 2025-06-05 | Tremfya | $144 |
| Ipsen Biopharmaceuticals | Meals · 2025-05-03 | Dysport | $14 |
| Lilly USA | Meals · 2025-04-09 | Emgality | $27 |
| Pfizer | Meals · 2025-04-08 | Nurtec Odt | $27 |
See earlier years (2024, 2023, 2022, 2021)
2024: $1,270
| Abbvie | Qulipta | $693 | 22 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $202 | 7 payments
|
| Lilly USA | Amyvid | $165 | 5 payments
|
| Amgen | Aimovig | $131 | 2 payments
|
| Pfizer | Nurtec Odt | $53 | 2 payments
|
| Eisai | Leqembi | $27 | 1 payment
|
2023: $1,334
| AbbVie | Ubrelvy | $765 | 26 payments
|
| Lilly USA | Emgality | $187 | 4 payments
|
| Pfizer | Nurtec Odt | $137 | 5 payments
|
| Marinus Pharmaceuticals | Ztalmy | $118 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo Xr | $46 | 3 payments
|
| Amgen | Aimovig | $44 | 1 payment
|
| Impel Pharmaceuticals | Trudhesa | $24 | 1 payment
|
| Ipsen Biopharmaceuticals | Dysport | $14 | 1 payment
|
2022: $1,055
| Biogen | None | $450 | 1 payment
|
| Abbvie | Qulipta | $206 | 3 payments
|
| Impel Pharmaceuticals | Trudhesa | $203 | 2 payments
|
| Teva Pharmaceuticals USA | Ajovy | $122 | 1 payment
|
| Eli Lilly and | Emgality | $42 | 1 payment
|
| Lilly USA | Emgality | $33 | 1 payment
|
2021: $447
| Biohaven Pharmaceuticals | Nurtec Odt | $142 | 2 payments
|
| AbbVie | Ubrelvy | $140 | 2 payments
|
| Lilly USA | Emgality | $72 | 1 payment
|
| Zogenix | Fintepla | $60 | 1 payment
|
| Teva Pharmaceuticals USA | Ajovy | $34 | 1 payment
|
Professional record
- NPI
- 1285297135
- Licence
- PA HS000240L
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2019-04-17
- NPI last updated
- 2024-10-03
- NPI record certified
- 2024-10-03
This is when the NPI record was last certified, not a medical board exam.